"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs"
AbilityPharma
ABOUT
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs"
AbilityPharma
LATEST NEWS
Press Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + infoPress Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + infoPress Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + infoPress Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + infoPress Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + infoPress Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + infoPress Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + infoPress Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + infoPress Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
Carretera antiga Amer nº 10
17007 • Girona
T. 972 909 999
E. info@neorgsite.com
http://www.neorgsite.com